Drug firm Bliss GVS Pharma has said its subsidiary Kremoint Pharma has cleared an inspection of its Ambernath facility in Maharashtra by the US health regulator. The inspection by the United States Food and Drug Administration (USFDA) was conducted from June 17-20, Bliss GVS Pharma said in a statement.
“The successful audit outcome from USFDA is a reflection of the steady progress that we are making into the mature pharma markets,” Bliss GVS Pharma VP-Strategy & Business Development Gagan Harsh Sharma said.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.